Press releases

The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Paris, October 1st. 2018. Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the

Paris, January 18th . 2018. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes such as septic shock, has appointed Martin Koch as Chief Operating Officer (COO). Martin Koch comes to Inotrem with more than 25 years of experience in the healthcare industry. Prior to joining

Paris, November 10, 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, today announced a R&D collaboration agreement with Roche Diagnostics to develop a companion diagnostic test using a soluble plasma circulating protein (sTREM-1) developed by Inotrem and the Roche proprietary

Paris, September 13 th. 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today that preclinical results show a direct and strong protective effect of its lead product candidate LR12 on vascular function during experimental septic shock. The firm was

Paris, France, September 13, 2016 – Inotrem SA, a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers. The principal objective of this first in-man phase I clinical trial, conducted

Paris and Nancy, France, March 13 2014 – Inotrem S.A., a French biotech company specialized in the control of immune reaction in acute inflammatory diseases, announced today the completion of its Series A financing round. With a total of €18 million, this round is the largest Series A round in